Anti-IL1RAP/CD3 Bispecific Antibody (BsAb) Is a Promising Novel and Effective Therapy for Acute Myeloid Leukemia (AML)

被引：0
|
作者：
Meng, Weixu
Del Real, Marissa
Wei, Guowei
Hernandez, Rochelle
Marcucci, Emanuela
Lin, Allen
Mcdonald, Tinisha
Zhao, Dandan
Wu, Herman
Carlesso, Nadia
Kwak, Larry W.
Li, Ling
Kuo, Ya-Huei
Stein, Anthony S.
Pullarkat, Vinod
Nakamura, Ryotaro
Rosen, Steven T.
Forman, Stephen J.
Zhang, Bin
Budde, Lihua
Marcucci, Guido
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1361
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Pre-Clinical Efficacy of the Anti-CD38 Monoclonal Antibody (mAb) Isatuximab in Acute Myeloid Leukemia (AML)
    Jelinek, Tomas
    Zabaleta, Aintzane
    Perez, Cristina
    Ajona, Daniel
    Alignani, Diego
    Rodriguez, Idoia
    Garate, Sonia
    Sarvide, Sarai
    Lasa, Marta
    Maiso, Patricia
    Prosper, Felipe
    Hajek, Roman
    San Miguel, Jesus F.
    Paiva, Bruno
    BLOOD, 2017, 130
  • [42] MECHANISM OF ACTION (MOA) OF THE ANTI-CD38 MONOCLONAL ANTIBODY ISATUXIMAB IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
    Zabaleta, Aintzane
    Jelinek, Tomas
    Simoes, Catia
    Perez, Cristina
    Prosper, Felipe
    Martinez-Cuadron, D.
    Bergua, J. M.
    Vives, S.
    Algarra, L.
    Tormo, M.
    Martinez, P.
    Serrano, J.
    Herrera, P.
    Ramos, F.
    Salamero, O.
    Lavilla, E.
    Sanz, M. A.
    Montesinos, P.
    San Miguel, J. F.
    Paiva, Bruno
    HAEMATOLOGICA, 2020, 105 : 60 - 60
  • [43] Anti-LYPD1/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Ovarian Cancer
    Lo, Amy A.
    Johnston, Jennifer
    Li, Ji
    Mandikian, Danielle
    Hristopoulos, Maria
    Clark, Robyn
    Nickles, Dorothee
    Liang, Wei-Ching
    Hotzel, Kathy
    Dunlap, Debra
    Thinh Pham
    Cai, Hao
    Ovacik, Meric
    Bravo-Perez, Daniel
    Mai, Elaine
    Slaga, Dionysos
    Ellerman, Diego
    Ziai, James
    Totpal, Klara
    Lee, Genee
    Boswell, C. Andrew
    Payandeh, Jian
    Wu, Yan
    Junttila, Teemu T.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (04) : 716 - 725
  • [44] Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors
    Root, Adam R.
    Guntas, Gurkan
    Katragadda, Madan
    Apgar, James R.
    Narula, Jatin
    Chang, Chew Shun
    Hanscom, Sara
    McKenna, Matthew
    Wade, Jason
    Meade, Caryl
    Ma, Weijun
    Guo, Yongjing
    Liu, Yan
    Duan, Weili
    Hendershot, Claire
    King, Amy C.
    Zhang, Yan
    Sousa, Eric
    Tam, Amy
    Benard, Susan
    Yang, Han
    Kelleher, Kerry
    Jin, Fang
    Piche-Nicholas, Nicole
    Keating, Sinead E.
    Narciandi, Fernando
    Lawrence-Henderson, Rosemary
    Arai, Maya
    Stochaj, Wayne R.
    Svenson, Kristine
    Mosyak, Lidia
    Lam, Khetemcnee
    Francis, Christopher
    Marquette, Kimberly
    Wroblewska, Liliana
    Zhu, H. Lily
    Sheehan, Alfredo Darmanin
    LaVallie, Edward R.
    D'Antona, Aaron M.
    Betts, Alison
    King, Lindsay
    Rosfjord, Edward
    Cunningham, Orla
    Lin, Laura
    Sapra, Puja
    Tchistiakova, Lioudmila
    Mathur, Divya
    Bloom, Laird
    MABS, 2021, 13 (01)
  • [45] Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study
    Ravandi, Farhad
    Bashey, Asad
    Stock, Wendy
    Foran, James M.
    Mawad, Raya
    Egan, Daniel
    Blum, William
    Yang, Allen
    Pastore, Alessandro
    Johnson, Chelsea
    Zheng, Shuo
    Yilmaz, Musa
    Mims, Alice S.
    BLOOD, 2020, 136
  • [46] Midostaurin abrogates CD33-directed UniCAR and CD33-CD3 bispecific antibody therapy in acute myeloid leukaemia
    Fasslrinner, Frederick
    Arndt, Claudia
    Koristka, Stefanie
    Feldmann, Anja
    Altmann, Heidi
    von Bonin, Malte
    Schmitz, Marc
    Bornhauser, Martin
    Bachmann, Michael
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (05) : 735 - 740
  • [47] Phase 1 Cohort Expansion of Flotetuzumab, a CD123xCD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Uy, Geoffrey L.
    Rettig, Michael P.
    Vey, Norbert
    Godwin, John
    Foster, Matthew C.
    Rizzieri, David A.
    Arellano, Martha L.
    Topp, Max S.
    Huls, Gerwin
    Jongen-Lavrencic, Mojca
    Martinelli, Giovanni
    Paolini, Stefania
    Ciceri, Fabio
    Carrabba, Matteo Giovanni
    Sweet, Kendra L.
    Ravandi, Farhad
    Church, Sarah E.
    Vadakekolathu, Jayakumar
    Rutella, Sergio
    Sun, Jichao
    Yang, Kang
    Baughman, Jan
    Curtis, Teia
    Timmeny, Erin
    Cali, Kerri
    Tran, Kathy
    Muth, John
    La Motte-Mohs, Ross
    Poirot, Camille
    Pallis, Athanasios
    Cesano, Alessandra
    Bonvini, Ezio
    Wigginton, Jon
    Lowenberg, Bob
    Davidson-Moncada, Jan K.
    DiPersio, John F.
    BLOOD, 2018, 132
  • [48] A Phase I Study of IGN523, a Novel Anti-CD98 Monoclonal Antibody in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
    Bixby, Dale
    Wieduwilt, Matthew J.
    Akard, Luke Paul
    Khoury, H. Jean
    Becker, Pamela S.
    Van Der Horst, Edward H.
    Ho, William
    Cortes, Jorge E.
    BLOOD, 2015, 126 (23)
  • [49] Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia
    Sisi Wang
    Lijun Peng
    Wenqian Xu
    Yuebo Zhou
    Ziyan Zhu
    Yushan Kong
    Stewart Leung
    Jin Wang
    Xiaoqiang Yan
    Jian-Qing Mi
    Frontiers of Medicine, 2022, 16 : 139 - 149
  • [50] Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia
    Hutmacher, Cornelia
    Volta, Laura
    Rinaldi, Francesco
    Murer, Patrizia
    Myburgh, Renier
    Manz, Markus G.
    Neri, Dario
    LEUKEMIA RESEARCH, 2019, 84
12345